- Home
- STEP vs BLLN Comparison
STEP vs BLLN Comparison
Compare STEP & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEP | BLLN |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.9B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | STEP | BLLN |
|---|---|---|
| Price | $62.43 | $82.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $76.71 | ★ $137.83 |
| AVG Volume (30 Days) | ★ 661.0K | 239.1K |
| Earning Date | 02-05-2026 | 12-09-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,535,264,000.00 | $254,136,000.00 |
| Revenue This Year | N/A | $98.01 |
| Revenue Next Year | $27.26 | $35.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 91.84 | ★ 254.30 |
| 52 Week Low | $40.07 | $80.00 |
| 52 Week High | $77.80 | $138.70 |
Technical Indicators
Market Signals| Indicator | STEP | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 42.60 |
| Support Level | $71.44 | $80.65 |
| Resistance Level | $74.65 | $87.54 |
| Average True Range (ATR) | 2.92 | 5.99 |
| MACD | -1.32 | -0.28 |
| Stochastic Oscillator | 3.49 | 17.40 |
Price Performance
Historical ComparisonAbout STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About BLLN BillionToOne Inc.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.